IGHG COVID-19 Statement
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.
The IGHG COVID-19 working group developed a statement to provide guidance to childhood, adolescent and young adult cancer survivors related to risk and additional preventive measures for COVID-19.
We are updating the statement as soon as new knowledge is available.
Version 3.0 of the statement is now published in English, Dutch, German, French, Italian, Czech, Greek, Polish, Portuguese, Spanish, Croatian, Slovene, Turkish, Chinese, Japanese and Hindi.
Please find here the IGHG COVID-19 statement:
- ENGLISH 2020 05 14 IGHG statement for COVID Final v3.0
- DUTCH_2020-05-14-IGHG-statement-for-COVID-Final_v3.0
- GERMAN_2020_05_14_IGHG_statement_for COVID_Final_v3.0
- FRENCH_2020_05_14_IGHG_statement_for_COVID_Final_v3.0
- ITALIAN_2020_05_14_IGHG_statement_for_COVID_Final_v3.0
- CZECH_2020_05_14_IGHG_statement_for COVID_Final_v3.0
- GREEK_2020_05_14_IGHG_statement_for_COVID_Final_v3.0
- POLISH_2020_05_14_IGHG_statement_for_COVID_Final_v3.0
- PORTUGUESE_2020_05_14_IGHG_statement_for_COVID_Final_v3.0
- ESPAÑOL_2020_05_14_IGHG_statement_for COVID_Final_v3.0
- CROATIAN_2020_05_14_IGHG_statement_for COVID_Final_v3.0
- SLOVENE_2020_05_14_IGHG_statement_for COVID_Final_v3.0
- TURKISH_2020_05_14_IGHG_statement_for COVID_Final_v3.0
- CHINESE_2020_05_14_IGHG_statement_for COVID_Final_v3.0
- JAPANESE_2020_05_14_IGHG_statement_for_COVID_Final_v3.0
- HINDI_2020_05_14_IGHG_statement_for COVID_Final_v3.0
The publication by Verbruggen et al. (2020) is now published in Pediatric Blood & Cancer
IGHG
The International Late Effects of Childhood Cancer Guideline Harmonization Group, IGHG, is a worldwide endeavor initiated by several national guideline groups and the Cochrane Childhood Cancer Group in partnership with the PanCare Guidelines Group to collaborate in guideline development.
Our main goal is to establish a common vision and integrated strategy for the surveillance of chronic health problems and subsequent cancers in childhood, adolescent, and young adult cancer survivors.
By international collaboration in guideline development we aim to reduce duplication of effort, optimize the quality of care, and improve quality of life for childhood, adolescent, and young adult cancer survivors.
We welcome all individuals who are willing to contribute to this initiative.
